FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2895550416> ?p ?o ?g. }

• W2895550416 abstract "Introduction: Temozolomide (TMZ) is part of the standard of care for treating glioblastoma multiforme (GBM), an aggressive primary brain tumor. New approaches are needed to enhance therapeutic efficacy and reduce toxicity. GBM tumor cells are dependent on glucose and glutamine while relying heavily on aerobic fermentation for energy metabolism. Restricted availability of glucose and glutamine may therefore reduce disease progression. Calorically restricted ketogenic diets (KD-R), which reduce glucose and elevate ketone bodies, offer a promising alternative in targeting energy metabolism because cancer cells cannot effectively burn ketones due to defects in the number, structure, and function of mitochondria. Similarly, oxaloacetate, which participates in the deamination of glutamate, has the potential to reduce the negative effects of excess glutamate found in many brain tumors, while hyperbaric oxygen therapy can reverse the hypoxic phenotype of tumors and reduce growth. We hypothesize that the combinatorial therapy of KD-R, hyperbaric oxygen, and oxaloacetate, could reduce or eliminate the need for TMZ in GBM patients. Methods: Our proposed approach for inhibiting tumor metabolism involved various combinations of the KD-R, oxaloacetate (2 mg/g), hyperbaric oxygen, and TMZ (20 mg/kg). This combinatorial therapy was tested on adult VM/Dk mice bearing the VM-M3/Fluc preclinical GBM model grown orthotopically. After 14 days, tumor growth was quantified via bioluminescence. A survival study was performed and the data were analyzed and portrayed in a Kaplan Meier plot. Preliminary dosage studies were used and strict diet and drug administration was maintained throughout the study. Results: The therapeutic effect of all treatments was powerful when administered under KD-R. The most promising survival advantage was seen in the two groups receiving oxaloacetate without TMZ. The survival of mice receiving TMZ was diminished due to its apparent toxicity. Among all groups, those receiving TMZ had the most significant reduction in tumor growth. The most powerful therapeutic effect was evident with combinations of these therapies. Conclusion: This study provides evidence for a potentially novel therapeutic regimen of hyperbaric oxygen, oxaloacetate, and the KD-R for managing growth and progression of VM-M3/Fluc GBM." @default.
• W2895550416 created "2018-10-12" @default.
• W2895550416 creator A5021162065 @default.
• W2895550416 creator A5050589914 @default.
• W2895550416 creator A5053210792 @default.
• W2895550416 creator A5067819286 @default.
• W2895550416 creator A5086992228 @default.
• W2895550416 date "2018-10-05" @default.
• W2895550416 modified "2023-09-25" @default.
• W2895550416 title "Nontoxic Targeting of Energy Metabolism in Preclinical VM-M3 Experimental Glioblastoma" @default.
• W2895550416 cites W1544910869 @default.
• W2895550416 cites W1559213768 @default.
• W2895550416 cites W1606666119 @default.
• W2895550416 cites W1984092376 @default.
• W2895550416 cites W1991479116 @default.
• W2895550416 cites W1992887184 @default.
• W2895550416 cites W1993034243 @default.
• W2895550416 cites W2002766055 @default.
• W2895550416 cites W2020812892 @default.
• W2895550416 cites W2031227547 @default.
• W2895550416 cites W2032940213 @default.
• W2895550416 cites W2038317423 @default.
• W2895550416 cites W2054062420 @default.
• W2895550416 cites W2054660542 @default.
• W2895550416 cites W2056795168 @default.
• W2895550416 cites W2064870692 @default.
• W2895550416 cites W2065064683 @default.
• W2895550416 cites W2072451938 @default.
• W2895550416 cites W2083888116 @default.
• W2895550416 cites W2092360365 @default.
• W2895550416 cites W2095568712 @default.
• W2895550416 cites W2103147617 @default.
• W2895550416 cites W2103953491 @default.
• W2895550416 cites W2114845975 @default.
• W2895550416 cites W2115813005 @default.
• W2895550416 cites W2120453252 @default.
• W2895550416 cites W2138788632 @default.
• W2895550416 cites W2139941871 @default.
• W2895550416 cites W2143497943 @default.
• W2895550416 cites W2150856099 @default.
• W2895550416 cites W2157414760 @default.
• W2895550416 cites W2157607856 @default.
• W2895550416 cites W2159719186 @default.
• W2895550416 cites W2160618105 @default.
• W2895550416 cites W2168074233 @default.
• W2895550416 cites W2295039857 @default.
• W2895550416 cites W2299317003 @default.
• W2895550416 cites W2336469753 @default.
• W2895550416 cites W2495715080 @default.
• W2895550416 cites W2531008215 @default.
• W2895550416 cites W2537345927 @default.
• W2895550416 cites W2552014047 @default.
• W2895550416 cites W2566067391 @default.
• W2895550416 cites W2589557260 @default.
• W2895550416 cites W2598707759 @default.
• W2895550416 cites W2747169154 @default.
• W2895550416 cites W2791283667 @default.
• W2895550416 cites W2794508608 @default.
• W2895550416 cites W4236412321 @default.
• W2895550416 cites W62898540 @default.
• W2895550416 doi "https://doi.org/10.3389/fnut.2018.00091" @default.
• W2895550416 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6186985" @default.
• W2895550416 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30349820" @default.
• W2895550416 hasPublicationYear "2018" @default.
• W2895550416 type Work @default.
• W2895550416 sameAs 2895550416 @default.
• W2895550416 citedByCount "9" @default.
• W2895550416 countsByYear W28955504162019 @default.
• W2895550416 countsByYear W28955504162020 @default.
• W2895550416 countsByYear W28955504162021 @default.
• W2895550416 countsByYear W28955504162023 @default.
• W2895550416 crossrefType "journal-article" @default.
• W2895550416 hasAuthorship W2895550416A5021162065 @default.
• W2895550416 hasAuthorship W2895550416A5050589914 @default.
• W2895550416 hasAuthorship W2895550416A5053210792 @default.
• W2895550416 hasAuthorship W2895550416A5067819286 @default.
• W2895550416 hasAuthorship W2895550416A5086992228 @default.
• W2895550416 hasBestOaLocation W28955504161 @default.
• W2895550416 hasConcept C104317684 @default.
• W2895550416 hasConcept C111133373 @default.
• W2895550416 hasConcept C111335760 @default.
• W2895550416 hasConcept C142724271 @default.
• W2895550416 hasConcept C161997846 @default.
• W2895550416 hasConcept C181199279 @default.
• W2895550416 hasConcept C202751555 @default.
• W2895550416 hasConcept C2777389519 @default.
• W2895550416 hasConcept C2778227246 @default.
• W2895550416 hasConcept C2779130545 @default.
• W2895550416 hasConcept C2779349466 @default.
• W2895550416 hasConcept C2781305896 @default.
• W2895550416 hasConcept C502942594 @default.
• W2895550416 hasConcept C515207424 @default.
• W2895550416 hasConcept C54009773 @default.
• W2895550416 hasConcept C55493867 @default.
• W2895550416 hasConcept C71924100 @default.
• W2895550416 hasConcept C86803240 @default.
• W2895550416 hasConcept C98274493 @default.
• W2895550416 hasConceptScore W2895550416C104317684 @default.
• W2895550416 hasConceptScore W2895550416C111133373 @default.
• W2895550416 hasConceptScore W2895550416C111335760 @default.

• next